Discover how AI and machine learning are reinventing covalent small molecule drug design. Learn what makes targeted covalent inhibitors unique, how algorithms optimize warhead reactivity and selectivity, and why generative models are accelerating covalent hit discovery.
Discover how KRAS evolved from an “undruggable” oncogene to a validated drug target. Learn how covalent KRASG12C inhibitors like sotorasib and adagrasib work, and explore emerging noncovalent strategies for targeting other KRAS mutations in lung, colorectal, and pancreatic cancer.